Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

The IIT Roorkee study on Efavirenz offers a new avenue for Chikungunya treatment, bringing optimism to patients and doctors ...

The study conducted by IIT Roorkee is supported by the Indian Council of Medical Research (ICMR). It has been published in a ...

Efavirenz (EFV), brand-named drugs such as Sustiva, is an antiretroviral drug utilized mostly for HIV/AIDS treatment and prevention. Efavirenz is a category of drugs that fall under non-nucleoside ...

IIT Roorkee researchers have discovered that Efavirenz, an HIV drug, may help treat Chikungunya by reducing virus replication in lab tests and mice models. While promising, clinical trials are needed ...

Roorkee researchers have identified a new potential treatment for Chinkungunya, indicate that Efavirenz, a widely used HIV ...

Efavirenz (EFV), sold under the brand names Sustiva among others, is an antiretroviral medication used to treat and prevent HIV/AIDS.

Scientists at IIT Roorkee have achieved a major breakthrough by identifying a potential drug for the treatment of chikungunya ...

Federal Circuit Ruling Potentially Upends Orange Book Patent Listing Requirements, Expert Analysis Reveals This ruling marks a pivotal moment in Hatch-Waxman practice, potentially altering how ...